Metastatic breast cancer Trials in Chicago, United States
Conditions / Metastatic breast cancer / Chicago, United States
Metastatic breast cancer has been the subject of sustained clinical investigation across multiple research sites.
51 total trials for this combination
Showing top 10 of 51 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | RECRUITING | PHASE1/PHASE2 |
| NCT05963997 | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT01307891 | Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer | COMPLETED | PHASE2 |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | COMPLETED | PHASE1 |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | RECRUITING | PHASE3 |
| NCT05216432 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | RECRUITING | PHASE1 |
| NCT06072612 | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | RECRUITING | PHASE3 |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | RECRUITING | PHASE3 |
| NCT02202746 | A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | TERMINATED | PHASE2 |